Dakota Wealth Management Buys 12,283 Shares of Exelixis, Inc. $EXEL

Key Points

• Dakota Wealth Management increased its stake in Exelixis by 97.9% in the second quarter, owning a total of 24,831 shares worth approximately $1,094,000.
• Exelixis reported $0.75 earnings per share for the quarter, surpassing analysts' expectations of $0.63, although its revenue decreased by 10.8% year-over-year.
• Institutional investors currently hold 85.27% of Exelixis's stock, with several large firms recently modifying their holdings.

Dakota Wealth Management grew its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 97.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,831 shares of the biotechnology company's stock after purchasing an additional 12,283 shares during the period. Dakota Wealth Management's holdings in Exelixis were worth $1,094,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Frank Rimerman Advisors LLC grew its stake in shares of Exelixis by 4.7% in the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company's stock valued at $234,000 after purchasing an additional 285 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Exelixis by 6.1% in the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company's stock valued at $195,000 after purchasing an additional 307 shares during the period. Rathbones Group PLC grew its stake in shares of Exelixis by 5.3% in the 1st quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company's stock valued at $253,000 after purchasing an additional 347 shares during the period. Larson Financial Group LLC grew its stake in shares of Exelixis by 9.2% in the 1st quarter. Larson Financial Group LLC now owns 4,367 shares of the biotechnology company's stock valued at $161,000 after purchasing an additional 367 shares during the period. Finally, Byrne Asset Management LLC grew its position in Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 400 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Exelixis Stock Performance

Shares of EXEL opened at $39.04 on Friday. The business's fifty day moving average price is $38.97 and its two-hundred day moving average price is $39.73. The firm has a market capitalization of $10.51 billion, a price-to-earnings ratio of 18.77, a PEG ratio of 0.81 and a beta of 0.32. Exelixis, Inc. has a 52 week low of $25.17 and a 52 week high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.63 by $0.12. The company had revenue of $568.26 million for the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm's quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of research analyst reports. Benchmark restated a "neutral" rating on shares of Exelixis in a research report on Monday, June 23rd. Stifel Nicolaus increased their price target on Exelixis from $38.00 to $41.00 and gave the stock a "hold" rating in a research report on Tuesday, July 29th. Guggenheim restated a "buy" rating and set a $45.00 price target on shares of Exelixis in a research report on Tuesday, July 29th. JMP Securities restated a "market outperform" rating and set a $50.00 price target on shares of Exelixis in a research report on Tuesday, July 29th. Finally, HC Wainwright decreased their price target on Exelixis from $53.00 to $46.00 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Exelixis has a consensus rating of "Moderate Buy" and an average target price of $44.42.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.